ArticleFrontiers in aging neuroscience2022
Oculomotor impairments in
Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms.Frontiers in aging neuroscience · 2025Pooled it
- Integrating Eye Tracking and Inertial Sensing for Enhanced Freezing of Gait Detection in Parkinson's Disease.The European journal of neuroscience · 2026Article
- Exploring eye movement abnormalities as objective biomarkers for Parkinson's disease utilizing virtual reality-based eye tracking.BMC neurology · 2026Article
- Eye Tracking in Parkinson's Disease: A Review of Oculomotor Markers and Clinical Applications.Brain sciences · 2025Review
- Diagnosis of Parkinson's disease by eliciting trait-specific eye movements in multi-visual tasks.Journal of translational medicine · 2025Article
- Smooth pursuit and memory saccades are impaired in early-stage Parkinson's disease patients.Frontiers in neurology · 2025Article
- Reduced maximal range of ocular movements and its response to acute levodopa challenge in Parkinson's disease.Frontiers in aging neuroscience · 2024Article
- Vestibular dysfunction in Parkinson's disease: a neglected topic.Frontiers in neurology · 2024Review
- Detecting Abnormal Eye Movements in Patients with Neurodegenerative Diseases - Current Insights.Eye and brain · 2024Review
- Oculomotor Dysfunction in Idiopathic and LRRK2-Parkinson's Disease and At-Risk Individuals.Journal of Parkinson's disease · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Reliable electrophysiological indicators are urgently needed in the precise evaluation of Parkinson's disease (PD). It is still elusive whether oculomotor performance is impaired or has clinical value in early PD. This study aims to explore oculomotor performance in newly diagnosed, drug-naïve PD and its correlation with clinical phenotype. Methods: Seventy-five patients with Results: Both Conclusion: Ocular movements are impaired in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.